Isofol Medical AB (FRA:5IU)
€ 0.0474 -0.0037 (-7.24%) Market Cap: 9.86 Mil Enterprise Value: -2.54 Mil PE Ratio: 0 PB Ratio: 1.11 GF Score: 33/100

Q3 2022 Isofol Medical AB (publ) Earnings Call Transcript

Nov 11, 2022 / 10:00AM GMT
Release Date Price: €0.0499 (+8.24%)
Operator

Welcome to the Isofol Medical Q3 2022 presentation. Afterwards, there will be a question-and-answer session. (Operator Instructions) Today, I'm pleased to present CEO Ulf Jungnelius; and CFO Gustaf Albèrt. Please begin your meeting.

Ulf Jungnelius;publ;CEO
Isofol Medical AB

()-

Thank you so much and welcome to our presentation of the third-quarter results of this year. We are at the, we told you before, closing down the AGENT study in accordance with the ethical and regulatory requirements.

If we go to the next slide, the disclaimer, please read it through while I go to slide number 4. And slide number 4 starts with Q3 highlights. So let's look at what happened during the third quarter of this year.

First of all, in early August, we presented the data from our randomized pivotal Phase 3 study. And unfortunately and sadly, it showed that we did not achieve the primary endpoint of overall response rate or the key secondary endpoint of progression-free survival. Two endpoints there were required for a positive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot